Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Perrigo To Launch Private Label Mucinex, Prevacid, With An Eye On Lipitor

This article was originally published in The Tan Sheet

Executive Summary

Private label giant Perrigo is readying generic competitors to Reckitt Benckiser’s Mucinex and Takeda Pharmaceuticals’ Prevacid, CEO Joseph Papa says.

You may also be interested in...



Perrigo Nutritional Dip Riles Analysts Amid Record Consumer Sales

A 14% decline in nutritional segment sales that slightly hampered Perrigo Co.’s consumer business revenue could affect the firm’s stock valuation if it cannot turn the division around, multiple analysts said. But Perrigo says the dip was expected and temporary,

Perrigo Nutritional Dip Riles Analysts Amid Record Consumer Sales

A 14% decline in nutritional segment sales that slightly hampered Perrigo Co.’s consumer business revenue could affect the firm’s stock valuation if it cannot turn the division around, multiple analysts said. But Perrigo says the dip was expected and temporary,

Brand-Boosting Schiff Nutrition Sees Upside In Top-Selling Supplements

Schiff Nutrition CEO Tarang Amin, a veteran of managing brands for Clorox and P&G, sees additional upside in top-selling brands such as MegaRed and Move Free. The firm also is de-emphasizing its struggling private label business.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS105256

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel